Phase III
Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.
NuCana halted enrollment of patients in the Phase III ACELERATE trial on the advice of the study’s Independent Safety and Data Monitoring Committee.
The Phase III NEPTUNE trial assessed the combination treatment as a first-line treatment in an “all-comers population,” with the primary analysis population being patients with a high tumor mutational burden.
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1.
In the trial, evinacumab showed a 49% decrease in LDL cholesterol from baseline compared to placebo, which showed a 2% increase.
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
Deciphera’s stock jumped from Monday’s close of $19.95 to $44.40 this morning after the company showed ripretinib provided 6.3 months of progression-free survival compared to one month from placebo.
PRESS RELEASES